anti-HER2 CAR T-cell therapy OmniCAR (Prescient Therapeutics)

N/A

Report date: 2025/01/26 19:00:39

Base Information

Drug Nameanti-HER2 CAR T-cell therapy OmniCAR (Prescient Therapeutics)

Drug Alias NameOmniCAR HER2 (Prescient Therapeutics)omniCAR HER2 (Prescient Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsOvarian NeoplasmsStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrescient Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrescient Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A